Alliance for Pandemic Preparedness

May 3, 2021

Weak Immunogenicity after a Single Dose of SARS-CoV-2 MRNA Vaccine in Treated Cancer Patients

Category:

Topic:

Keywords (Tags):

  • Nearly half of patients with cancer (CP) at a hospital in France showed no anti-spike antibody response four weeks after one dose of the Pfizer-BioNTech vaccine, while 100% of healthcare workers (HCW) vaccinated at the same time (between February 17 and March 18, 2021) had developed anti-spike antibodies (seroconversion). Anti-S IgG titers were also significantly higher in HCWs than among seropositive CPs (680 vs 315 UA/mL). Age older than 65 (aOR = 3.6) and chemotherapy treatment (aOR = 4.3) were associated with lack of seroconversion among CP. No symptomatic COVID-19 cases occurred between the two doses in either CPs or HCWs.

Palich et al. (Apr 2021). Weak Immunogenicity after a Single Dose of SARS-CoV-2 MRNA Vaccine in Treated Cancer Patients. Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.04.020